Innovative delivery of DNA and RNA vaccines for melanoma treatment
Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma.
This study is testing a new way to deliver DNA and RNA vaccines directly into the skin to help your body fight melanoma, using a special device that makes it easy and painless, while also personalizing the treatment based on your unique tumor.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Orlance, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10932954 on NIH RePORTER |
What this research studies
This research focuses on developing a next-generation Gene Gun that delivers DNA and RNA vaccines directly into skin cells to stimulate a strong immune response against melanoma. By sequencing tumors from individual patients, the study aims to identify personalized neoantigens that can be targeted with these vaccines. The Gene Gun technology allows for painless delivery of low doses of vaccines, which could lead to effective localized and systemic immune responses. This approach seeks to overcome limitations of current vaccine delivery methods, such as high doses and storage challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma who may benefit from personalized cancer vaccines.
Not a fit: Patients with non-melanoma skin cancers or those who do not have identifiable neoantigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for melanoma patients through personalized immunotherapy.
How similar studies have performed: Previous research has shown promise in using similar gene delivery technologies for cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Seattle, United States
- Orlance, INC. — Seattle, United States (Active)
Researchers
- Principal investigator: Frizzell, Hannah — Orlance, INC.
- Study coordinator: Frizzell, Hannah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.